Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.

Goldman, JW; Dvorkin, M; Chen, Y; Reinmuth, N; Hotta, K; Trukhin, D; Statsenko, G; Hochmair, MJ; Özgüroğlu, MUSTAFA; Ji, JH; Garassino, MC; Voitko, O; Poltoratskiy, A; Ponce, S; Verderame, F; Havel, L; Bondarenko, I; Każarnowicz, A; Losonczy, G; Conev, NV; Armstrong, J; Byrne, N; Thiyagarajah, P; Jiang, H; Paz-Ares, L; CASPIAN, investigators.

doi:10.1016/s1470-2045(20)30539-8

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.

Goldman J., Dvorkin M., Chen Y., Reinmuth N., Hotta K., Trukhin D., ...Daha Fazla

The Lancet. Oncology, cilt.22, ss.51-65, 2021 (SCI-Expanded, ESCI, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 22
Basım Tarihi: 2021
Doi Numarası: 10.1016/s1470-2045(20)30539-8
Dergi Adı: The Lancet. Oncology
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE
Sayfa Sayıları: ss.51-65
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

We present a case of a 69 year old man with phimosis associated with immunotherapy with durvalumab for metastatic non-small-cell lung cancer. The patient developed vitiligo like dermatosis after the induction dose of durvalumab, subsequent administration of the immunotherapy the patient developed a fibrous ring of the foreskin. Immune-mediated adverse reactions have been described after the use of durvalumab, but, to our knowledge, there are no reports of phimosis and vitiligo like reactions.